Literature DB >> 26860940

Advances in time course extracellular production of human pre-miR-29b from Rhodovulum sulfidophilum.

Patrícia Pereira1, Augusto Q Pedro1, Joana Tomás1, Cláudio J Maia1, João A Queiroz1, Ana Figueiras1,2, Fani Sousa3.   

Abstract

The present study reports the successful production of human pre-miR-29b both intra- and extracellularly in the marine phototrophic bacterium Rhodovulum sulfidophilum using recombinant RNA technology. In a first stage, the optimal transformation conditions (0.025 μg of plasmid DNA, with a heat-shock of 2 min at 35 °C) were established, in order to transfer the pre-miR-29b encoding plasmid to R. sulfidophilum host. Furthermore, the extracellular recovery of this RNA product from the culture medium was greatly improved, achieving quantities that are compatible with the majority of applications, namely for in vitro or in vivo studies. Using this system, the extracellular human pre-miR-29b concentration was approximately 182 μg/L, after 40 h of bacterial growth, and the total intracellular pre-miR-29b was of about 358 μg/L, at 32 h. At the end of the fermentation, it was verified that almost 87 % of cells were viable, indicating that cell lysis is minimized and that the extracellular medium is not highly contaminated with the host intracellular ribonucleases (RNases) and endotoxins, which is a critical parameter to guarantee the microRNA (miRNA) integrity. These findings demonstrate that pre-miRNAs can be produced by recombinant RNA technology, offering novel clues for the production of natural pre-miRNA agents for functional studies and RNA interference (RNAi)-based therapeutics.

Entities:  

Keywords:  Extracellular production; RNAi technology; Recombinant human pre-miR-29b; Rhodovulum sulfidophilum; Transformation efficiency

Mesh:

Substances:

Year:  2016        PMID: 26860940     DOI: 10.1007/s00253-016-7350-x

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  9 in total

Review 1.  Bioengineered non-coding RNA agent (BERA) in action.

Authors:  Zhijian Duan; Ai-Ming Yu
Journal:  Bioengineered       Date:  2016-07-14       Impact factor: 3.269

2.  New insights for therapeutic recombinant human miRNAs heterologous production: Rhodovolum sulfidophilum vs Escherichia coli.

Authors:  Patrícia Pereira; Augusto Q Pedro; João A Queiroz; Ana R Figueiras; Fani Sousa
Journal:  Bioengineered       Date:  2017-03-10       Impact factor: 3.269

3.  Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.

Authors:  Hannah Petrek; Neelu Batra; Pui Yan Ho; Mei-Juan Tu; Ai-Ming Yu
Journal:  Appl Microbiol Biotechnol       Date:  2019-06-11       Impact factor: 4.813

4.  Challenges to optimizing RNA nanostructures for large scale production and controlled therapeutic properties.

Authors:  Morgan Chandler; Martin Panigaj; Lewis A Rolband; Kirill A Afonin
Journal:  Nanomedicine (Lond)       Date:  2020-05-26       Impact factor: 5.307

Review 5.  RNA therapy: Are we using the right molecules?

Authors:  Ai-Ming Yu; Chao Jian; Allan H Yu; Mei-Juan Tu
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

Review 6.  Marine Purple Photosynthetic Bacteria as Sustainable Microbial Production Hosts.

Authors:  Mieko Higuchi-Takeuchi; Keiji Numata
Journal:  Front Bioeng Biotechnol       Date:  2019-10-11

Review 7.  Novel approaches for efficient  in vivo fermentation production of noncoding RNAs.

Authors:  Ai-Ming Yu; Neelu Batra; Mei-Juan Tu; Colleen Sweeney
Journal:  Appl Microbiol Biotechnol       Date:  2020-01-17       Impact factor: 4.813

Review 8.  A guide to large-scale RNA sample preparation.

Authors:  Lorenzo Baronti; Hampus Karlsson; Maja Marušič; Katja Petzold
Journal:  Anal Bioanal Chem       Date:  2018-03-15       Impact factor: 4.142

Review 9.  mRNA, a Revolution in Biomedicine.

Authors:  Bruno Baptista; Rita Carapito; Nabila Laroui; Chantal Pichon; Fani Sousa
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.